COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00209521
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : June 11, 2010
Information provided by:
Eisai Inc.

Brief Summary:
This is an exploratory clinical trial designed to examine the efficacy, safety and tolerability of fospropofol (AQUAVAN) Injection compared to propofol (DISOPRIVAN) Injectable Emulsion when used to preoperatively sedate, induce, and maintain general anesthesia and to postoperatively sedate patients undergoing elective coronary artery surgery.

Condition or disease Intervention/treatment Phase
Ischemic Coronary Artery Disease Coronary Artery Bypass Surgery Drug: fospropofol Drug: propofol Phase 2

Detailed Description:

This Phase 2, open-label, single-center, randomized clinical trial was designed to examine the efficacy and tolerability of AQUAVAN® Injection (hereafter, referred to as AQUAVAN) when used to preoperatively sedate, induce, and maintain general anesthesia and to postoperatively sedate patients undergoing elective coronary artery surgery. Eligible patients were randomized to either AQUAVAN or DISOPRIVAN® Injectable Emulsion (hereafter, referred to as DISOPRIVAN) following screening and prior to their arrival in the surgical suite.

On the day of surgery, after the administration a 0.5 mg/kg bolus dose of lignocaine, preoperative sedation began using the target-controlled infusion (TCI) system to target desired sedation plasma concentrations of either AQUAVAN or DISOPRIVAN, depending on the randomization schedule.

The Bispectral (BIS) Index was used to guide study drug administration; target BIS ranges were 60 to 80 for sedation and 40 to 60 for the maintenance of anesthesia. Adequate sedative/hypnotic effect during surgical anesthesia was characterized by the portion of time within the target BIS Index range versus total surgical time. Following this, during postsurgical sedation, inadequate sedative/hypnotic effect was characterized by the number, duration, and magnitude of BIS scores outside of the target range versus total postsurgical sedation time. During postsurgical sedation, the Modified Ramsey Scale was used as an additional clinical tool to evaluate the state of sedation, with an attempt to maintain the score between 3 and 5.

The overall quality of induction, maintenance and ease of control of anesthesia, and quality of sedation before and during cardiopulmonary bypass (CPB), were each graded by the anesthesiologist.

Continuous monitoring of blood pressure and heart rate were used to assess the hemodynamic effect of study drug. Hypertension and hypotension were defined as excursions of >/= 20% from the baseline value.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2, Randomized Study of AQUAVAN® Injection In Elective Coronary Artery Surgery With Comparison to DISOPRIVAN® Injectable Emulsion
Study Start Date : June 2002
Actual Primary Completion Date : July 2003
Actual Study Completion Date : July 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Propofol

Arm Intervention/treatment
Experimental: fospropofol Drug: fospropofol
Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
Other Names:
  • fospropofol disodium
  • E2083
  • GPI-15715

Active Comparator: propofol Drug: propofol
Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
Other Names:
  • Disoprivan
  • propofol injectable emulsion

Primary Outcome Measures :
  1. Median time (minutes) to loss of consciousness from induction start (reported as median and range). [ Time Frame: Day 1 ]

Secondary Outcome Measures :
  1. Median time (minutes) to induction from start of infusion (reported as median and range). [ Time Frame: Day 1 ]
  2. Time (minutes) to intubation from induction start (reported as median and range). [ Time Frame: Day 1 ]
  3. Time (minutes) to extubation from end of infusion (reported as median and range). [ Time Frame: Day 1 ]
  4. Time (minutes) to last suture from induction start (reported as median and range). [ Time Frame: Day 1 ]
  5. Time (minutes) to full awareness from end of infusion (reported as median and range). [ Time Frame: Day 1 ]
  6. Median time from End of Infusion to First Modified Ramsey Score of 3 (reported as median and range). [ Time Frame: Day 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients were between the ages of 21 and 70 years, inclusive.
  2. Patients were scheduled for first-time elective coronary artery bypass graft surgery, with 1 to 4 grafts planned.
  3. Patients had an American Society of Anesthesiologists (ASA) Physical Classification System status of II or III.
  4. Patients had a "good" left ventricular function as defined by a cardiac ejection fraction >=50% measured by cardiac catheterization or other quantitative technique.
  5. Patients provided written Informed Consent after receiving a full explanation of the extent and nature of the study and were willing to comply with the study procedures.
  6. Patients, if female, were surgically sterile or postmenopausal.

Exclusion Criteria:

  1. Patient had prior coronary bypass grafting or other cardiac surgery.
  2. Patient had uncontrolled hypertension (diastolic >110 mm Hg) or required additional intervention while hospitalized prior to surgery to control blood pressure.
  3. Patient had a medical history of renal disease or creatinine >1.4 mg/dL.
  4. Patient had known hemodynamically significant valvular abnormalities, except Grade 1 tricuspid or mitral insufficiency.
  5. Patient had severe obesity, defined as a body mass index (BMI) >35.
  6. Patient failed the Allen's Test to confirm the patency of the ulnar artery.
  7. Patient had severe or uncontrolled systemic illness (e.g., pulmonary disease, cancer, endocrine abnormalities).
  8. Patient had insulin-dependent diabetes.
  9. Patient had a history of stroke or current neurological disease (e.g., dementia, neuropathy), as determined by the Investigator.
  10. Patient had anticipated difficulties with intubation, in the judgment of the Investigator.
  11. Patient had a history of alcohol abuse, as determined by the Investigator;
  12. Patient had participated in an investigational drug study within 1 month prior to study start.
  13. Patient had donated >300 mL of blood within 1 month prior to study start.
  14. Patient had a positive medical history for drug abuse.
  15. Patient had a known infection with human immunodeficiency virus (HIV), Hepatitis B, and/or Hepatitis C.
  16. Patient had any history of anxiety or psychiatric illness or was currently using antidepressants, monoamine oxidase (MAO) inhibitors, anti-anxiety medications or other drugs with central nervous system (CNS) effects prior to their preoperative hospital stay.
  17. Patient had uncorrected visual problems, including cataracts, glaucoma, or any significant abnormalities found on fundoscopic examination that would interfere with visual assessment of drug safety.
  18. Patient had any history of adverse reaction to any opiate or anesthetic agent.
  19. Patient, if male, did not agree to use an effective method of birth control between the time of screening and end of study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00209521

Sponsors and Collaborators
Eisai Inc.
Layout table for investigator information
Study Director: James Vornov, PhD,MD Eisai Inc.
Layout table for additonal information
Responsible Party: James Vornov, MD, PhD, Guilford Pharmaceuticals, Inc. Identifier: NCT00209521    
Other Study ID Numbers: 3000-0104
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: June 11, 2010
Last Verified: June 2010
Keywords provided by Eisai Inc.:
Coronary Artery Bypass Surgery
AQUAVAN® Injection
DISOPRIVAN® Injectable Emulsion.
ischemic coronary artery disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General